SG11201806682TA - Tlr7 agonist maleate salt, crystalline forms c, d and e thereof, preparation methods and uses of maleate salt and crystalline forms - Google Patents

Tlr7 agonist maleate salt, crystalline forms c, d and e thereof, preparation methods and uses of maleate salt and crystalline forms

Info

Publication number
SG11201806682TA
SG11201806682TA SG11201806682TA SG11201806682TA SG11201806682TA SG 11201806682T A SG11201806682T A SG 11201806682TA SG 11201806682T A SG11201806682T A SG 11201806682TA SG 11201806682T A SG11201806682T A SG 11201806682TA SG 11201806682T A SG11201806682T A SG 11201806682TA
Authority
SG
Singapore
Prior art keywords
crystalline forms
maleate salt
salt
preparation methods
tlr7 agonist
Prior art date
Application number
SG11201806682TA
Other languages
English (en)
Inventor
Zhaozhong Ding
Fei Sun
Yinghu Hu
Yilong Zhou
Zheng Wang
Ling Yang
Original Assignee
Chia Tai Tianqing Pharmaceutical Group Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chia Tai Tianqing Pharmaceutical Group Co Ltd filed Critical Chia Tai Tianqing Pharmaceutical Group Co Ltd
Publication of SG11201806682TA publication Critical patent/SG11201806682TA/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/01Hydrocarbons
    • A61K31/015Hydrocarbons carbocyclic
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
SG11201806682TA 2016-02-05 2017-02-04 Tlr7 agonist maleate salt, crystalline forms c, d and e thereof, preparation methods and uses of maleate salt and crystalline forms SG11201806682TA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201610082030.0A CN107043380A (zh) 2016-02-05 2016-02-05 一种tlr7激动剂的马来酸盐、其晶型c、晶型d、晶型e、制备方法和用途
PCT/CN2017/072890 WO2017133683A1 (zh) 2016-02-05 2017-02-04 一种tlr7激动剂的马来酸盐、其晶型c、晶型d、晶型e及其制备方法和用途

Publications (1)

Publication Number Publication Date
SG11201806682TA true SG11201806682TA (en) 2018-09-27

Family

ID=59500111

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201806682TA SG11201806682TA (en) 2016-02-05 2017-02-04 Tlr7 agonist maleate salt, crystalline forms c, d and e thereof, preparation methods and uses of maleate salt and crystalline forms

Country Status (23)

Country Link
US (2) US10780091B2 (https=)
EP (1) EP3412671B1 (https=)
JP (1) JP6898336B2 (https=)
KR (1) KR102393279B1 (https=)
CN (2) CN107043380A (https=)
AR (1) AR107547A1 (https=)
AU (1) AU2017215800B2 (https=)
CA (1) CA3013682C (https=)
CL (1) CL2018002089A1 (https=)
DK (1) DK3412671T3 (https=)
EA (1) EA038794B1 (https=)
ES (1) ES2834303T3 (https=)
HU (1) HUE052211T2 (https=)
IL (1) IL260965B (https=)
MX (1) MX374295B (https=)
MY (1) MY196762A (https=)
NZ (1) NZ745231A (https=)
PH (1) PH12018501644B1 (https=)
SG (1) SG11201806682TA (https=)
TW (1) TWI778951B (https=)
UA (1) UA123781C2 (https=)
WO (1) WO2017133683A1 (https=)
ZA (1) ZA201805185B (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107043379A (zh) 2016-02-05 2017-08-15 正大天晴药业集团股份有限公司 一种tlr7激动剂的晶型a、其制备方法和医药用途
CN107043378A (zh) * 2016-02-05 2017-08-15 正大天晴药业集团股份有限公司 一种吡咯并[3,2-d]嘧啶类化合物的制备方法及其中间体
CN107043380A (zh) 2016-02-05 2017-08-15 正大天晴药业集团股份有限公司 一种tlr7激动剂的马来酸盐、其晶型c、晶型d、晶型e、制备方法和用途
CN112105620B (zh) * 2018-05-25 2026-02-24 正大天晴药业集团股份有限公司 用于治疗肺癌的tlr7激动剂及其药物组合
JP7287708B2 (ja) 2019-02-08 2023-06-06 プロジェニア インコーポレイテッド Toll-like受容体7または8アゴニストとコレステロールの結合体およびその用途
JP7811014B2 (ja) 2020-03-02 2026-02-04 プロジェニア インコーポレイテッド 病原菌外壁成分基盤の生病原体模倣ナノ粒子及びその製造方法
CN116322751A (zh) 2020-08-04 2023-06-23 蛋白科技先锋 包含能够动力学控制的佐剂的mRNA疫苗
JP2023536954A (ja) 2020-08-04 2023-08-30 プロジェニア インコーポレイテッド 活性化部位が一時的に不活性化したトール様受容体7または8作用薬と機能性薬物の結合体およびその用途
US20230355750A1 (en) 2020-08-04 2023-11-09 Progeneer Inc. Kinetically acting adjuvant ensemble

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3376479B2 (ja) * 1991-08-12 2003-02-10 武田薬品工業株式会社 縮合ピリミジン誘導体、その製造法および用途
ATE283855T1 (de) 1996-07-03 2004-12-15 Sumitomo Pharma Neue purinderivate
NZ504800A (en) 1997-11-28 2001-10-26 Sumitomo Pharma 6-Amino-9-benzyl-8-hydroxy-purine derivatives and interferon inducers, antiviral agents, anticancer agents and therapeutic agents for immunologic diseases thereof
ES2577514T3 (es) 2005-08-22 2016-07-15 The Regents Of The University Of California Antagonistas de TLR
CA2691444C (en) 2007-06-29 2016-06-14 Gilead Sciences, Inc. Purine derivatives and their use as modulators of toll-like receptor 7
CA2707030A1 (en) 2007-08-03 2009-02-12 Pfizer Limited Imidazopyridinones
ES2467108T3 (es) 2008-12-09 2014-06-11 Gilead Sciences, Inc. Moduladores de receptores tipo toll
EP2670244B1 (en) 2011-02-04 2018-04-11 Duquesne University of The Holy Spirit Bicyclic and tricyclic pyrimidine tyrosine kinase inhibitors with antitubulin activity and methods of treating a patient
EP2800569B1 (en) 2012-01-05 2018-07-25 Northeastern University Allosteric modulators of cb1 cannabinoid receptors
LT2906563T (lt) * 2012-10-10 2018-06-11 Janssen Sciences Ireland Uc Pirolo[3,2-d]pirimidino dariniai virusinių infekcijų ir kitų ligų gydymui
US9550785B2 (en) 2012-11-20 2017-01-24 Glaxosmithkline Llc Pyrrolopyrimidines as therapeutic agents for the treatment of diseases
KR20150085081A (ko) 2012-11-20 2015-07-22 글락소스미스클라인 엘엘씨 신규 화합물
MX358025B (es) 2012-11-20 2018-08-02 Glaxosmithkline Llc Star Compuestos novedosos.
KR20160124157A (ko) 2014-02-20 2016-10-26 글락소스미스클라인 인털렉츄얼 프로퍼티 (넘버 2) 리미티드 인간 인터페론의 유도인자로서의 피롤로[3,2]피리미딘 유도체
JP6484253B2 (ja) * 2014-05-01 2019-03-13 ノバルティス アーゲー Toll様受容体7アゴニストとしての化合物および組成物
EA032487B1 (ru) 2014-05-01 2019-06-28 Новартис Аг Соединения и композиции в качестве агонистов toll-подобного рецептора 7
HUE054672T2 (hu) 2014-08-15 2021-09-28 Chia Tai Tianqing Pharmaceutical Group Co Ltd TLR7 agonistaként alkalmazott pirrolopirimidin vegyületek
CN105367576A (zh) * 2014-08-15 2016-03-02 正大天晴药业集团股份有限公司 作为tlr7激动剂的吡咯并嘧啶化合物
CN105732635A (zh) 2014-12-29 2016-07-06 南京明德新药研发股份有限公司 一类Toll样受体7激动剂
TWI714661B (zh) 2015-11-05 2021-01-01 法商賽諾菲公司 新穎念珠藻素化合物及接合物、其製備與其治療用途
CA3004173C (en) 2015-11-05 2020-07-14 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. 7-(thiazol-5-yl)pyrrolopyrimidine compound as tlr7 agonist
CR20180310A (es) 2015-11-05 2018-11-30 Basf Se Oxadiazoles sustituidos para combatir hongod fitopatógenos
CN107043380A (zh) 2016-02-05 2017-08-15 正大天晴药业集团股份有限公司 一种tlr7激动剂的马来酸盐、其晶型c、晶型d、晶型e、制备方法和用途
CN107043377A (zh) * 2016-02-05 2017-08-15 正大天晴药业集团股份有限公司 一种tlr7激动剂的三氟乙酸盐、晶型b及其制备方法、药物组合物和用途
CN107043378A (zh) * 2016-02-05 2017-08-15 正大天晴药业集团股份有限公司 一种吡咯并[3,2-d]嘧啶类化合物的制备方法及其中间体
CN107043379A (zh) 2016-02-05 2017-08-15 正大天晴药业集团股份有限公司 一种tlr7激动剂的晶型a、其制备方法和医药用途

Also Published As

Publication number Publication date
HK1259175A1 (zh) 2019-11-29
US20200368241A1 (en) 2020-11-26
IL260965B (en) 2022-02-01
CN107043380A (zh) 2017-08-15
JP2019505532A (ja) 2019-02-28
AR107547A1 (es) 2018-05-09
EA038794B1 (ru) 2021-10-20
NZ745231A (en) 2022-07-29
US20190070179A1 (en) 2019-03-07
PH12018501644B1 (en) 2022-09-07
PH12018501644A1 (en) 2019-06-03
EP3412671A4 (en) 2019-07-24
DK3412671T3 (da) 2020-11-09
MX2018009500A (es) 2018-12-11
ZA201805185B (en) 2024-08-28
BR112018015881A2 (pt) 2018-12-26
UA123781C2 (uk) 2021-06-02
KR20180104116A (ko) 2018-09-19
CA3013682C (en) 2022-06-21
AU2017215800B2 (en) 2020-08-20
CN108602830B (zh) 2020-07-28
JP6898336B2 (ja) 2021-07-07
US10780091B2 (en) 2020-09-22
HUE052211T2 (hu) 2021-04-28
EP3412671B1 (en) 2020-09-16
WO2017133683A1 (zh) 2017-08-10
CL2018002089A1 (es) 2018-12-07
MY196762A (en) 2023-05-03
ES2834303T3 (es) 2021-06-17
KR102393279B1 (ko) 2022-05-02
CA3013682A1 (en) 2017-08-10
AU2017215800A1 (en) 2018-08-30
EP3412671A1 (en) 2018-12-12
CN108602830A (zh) 2018-09-28
TWI778951B (zh) 2022-10-01
TW201728588A (zh) 2017-08-16
MX374295B (es) 2025-03-06
EA201891770A1 (ru) 2019-01-31

Similar Documents

Publication Publication Date Title
ZA201805185B (en) Tlr7 agonist maleate salt, crystalline forms c, d and e thereof, preparation methods and uses of maleate salt and crystalline forms
SA520411222B1 (ar) مركبات بوصفها معدلات لعامل باديء حقيقي النواة 2ب وتركيبات وطرق
PH12020550703A1 (en) Sulfonamide compounds and use thereof
NZ747259A (en) Soluble c5ar antagonists
PH12018500777A1 (en) Farnesoid x receptor modulators
PH12017500281A1 (en) Pyrrolopyrimidine compounds used as tlr7 agonist
MX2018012087A (es) Compuestos agonistas de gpr119 y metodo para tratar enfermedades y afecciones mediado a traves de gpr119.
EA201990388A1 (ru) Пиперидиновые модуляторы рецепторов cxcr7
NZ729037A (en) Carboxylic acid compound, method for preparation thereof, and use thereof
TN2018000395A1 (en) New (hetero)aryl-substituted-piperidinyl derivatives, a process for their preparation and pharmaceutical compositions containing them
EA033168B1 (ru) СТИМУЛЯТОРЫ sGC
MX393820B (es) Derivado de ?-aminoácido tricíclico fusionado, método de preparación, y uso médico del mismo.
SG11201806683UA (en) Tlr7 agonist crystalline form a, preparation method and use thereof
PH12015502802A1 (en) Formulation comprising a hypolipidemic agent
EA201691538A1 (ru) Способ получения солей вортиоксетина
MX2019012454A (es) Compuesto solido cristalino novedoso de clorhidrato de 3-fenil-4-propil-1-(piridin-2-il)-1h-pirazol-5-ol.
MX2019004294A (es) Derivados de fenilamina 4-sustituidos y su uso para proteger cultivos al combatir microorganismos fitopatogenicos indeseados.
PH12019500822A1 (en) Crystalline forms of eravacycline
MA39715A (fr) Formes polymorphes de l'acide 4,5-dihydro-1h-pyrrolo[2,3-f]quinoline-2,7,9-tricarboxylique et de son sel de disodium, procédé de préparation desdites formes polymorphes et leur utilisation
MX2016004963A (es) Sal y formas cristalinas de inhibidores de quinasa tipo polo-4.
EP4295916A3 (en) Salts of 4-amino-n-(1-((3-chloro-2-fluorophenyl)amino)-6-methylisoquinolin-5-yl)thieno[3,2-d]pyrimidine-7-carboxamide, and crystalline forms thereof
IN2014MN01671A (https=)
MX2017008074A (es) DERIVADOS DE IMIDAZOPIRIDAZINA COMO INHIBIDORES DE FOSFOINOSITIDA-3-QUINASAS BETA (PI3Kß).
MY209356A (en) A xinafoate salt of a jak inhibiting compound
MX2017008076A (es) DERIVADOS DE IMIDAZOPIRIDAZINA ENLAZADOS A HETEROCICLILO COMO INHIBIDORES DE PI3Kß.